Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

THOR MEDICAL Aktie

>THOR MEDICAL Aktienkurs

0.353 EUR (Tradegate)

Ask: 0.358 EUR / 4500 Stück

Bid: 0.348 EUR / 5000 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

THOR MEDICAL Aktie über LYNX handeln

Intraday

1 Jahr

>THOR MEDICAL Performance

1 Woche: +1,1%

1 Monat: +12,6%

3 Monate: -7,1%

6 Monate: +64,2%

1 Jahr: +44,7%

laufendes Jahr: +61,2%

>THOR MEDICAL Aktie

Name:

THOR MEDICAL ASA NK 0,20

Land:

Norwegen

Sektor:

Gesundheit

ISIN/ Wkn:

NO0010597883 / A1H64K

Symbol/ Ticker:

8NN (Frankfurt)

Kürzel:

FRA:8NN, ETR:8NN, 8NN:GR

Index:

Webseite:

https://www.thormedical.n..

Profil:

Thor Medical ASA is a prominent player in the biom..
>Volltext..

Marktkapitalisierung:

123.65 Mio. EUR

Unternehmenswert:

105.53 Mio. EUR

Umsatz:

0.01 Mio. EUR

EBITDA:

-4.48 Mio. EUR

Nettogewinn:

-4.97 Mio. EUR

Gewinn je Aktie:

-0.02 EUR

Schulden:

0.73 Mio. EUR

Liquide Mittel:

18.92 Mio. EUR

Operativer Cashflow:

-3.61 Mio. EUR

Bargeldquote:

8.01

Umsatzwachstum:

Gewinnwachstum:

-332.45%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

THOR MEDICAL, NORDIC NANOVECTOR

Letzte Datenerhebung:

17.12.25

>THOR MEDICAL Kennzahlen

Aktien/ Unternehmen:

Aktien: 354.08 Mio. St.

Frei handelbar: 61.69%

Leerverk. Aktien: -

Rückkaufquote: -18.3%

Mitarbeiter: 9

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 25.64%

Bewertung:

KGV: -

KGV lG: -

KUV: 11225.58

KBV: 3

PEG-Ratio: -0.06

EV/EBITDA: -

Rentabilität:

Bruttomarge: -36400%

Gewinnmarge: -58900%

Operative Marge: -65300%

Managementeffizenz:

Gesamtkaprendite: -13.37%

Eigenkaprendite: -16.06%

>THOR MEDICAL Peer Group

Es sind 25 Aktien bekannt.

>THOR MEDICAL Chart & Kurs - Tradegate

>THOR MEDICAL News

07.10.25 - 08:03

Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer (Business Wire)

Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS WIRE)--Epsilogen, the world's leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development. Dr. Oliva joins Epsilogen from BerGenBio, where she served as Chief Medical Officer from 2022. Prior to this role, Dr. Oliva was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA, where she led a cross-functional team of oncology subject matter experts and established and led the IQVIA Oncology Global Scientific Advisory Board. Dr. Oliva has also held senior positions, leading oncology development programs, at Nordic Nanovector, Takeda Pharmaceuticals, GSK and Eli Lilly. Tim Wilson, CE...

29.08.25 - 07:01

Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement (Cision)

Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinical-stage radiopharmaceutical company, have entered into a strategic agreement for Thorium-228 radioisotopes to supply the Phase 3 clinical program for Radspherin®, Oncoinvent's lead product candidate. Under the terms of the agreement, Thor Medical will supply Thorium-228 from AlphaOne, the company's first commercial-scale manufacturing plant currently under construction. Thorium-228 from Thor Medical will serve as the starting material for the...

15.12.24 - 21:39	XFRA : CAPITAL ADJUSTMENT INFORMATION - 16.12.2024 - NO0010597883 (XETRA)
	Das Instrument 8NN NO0010597883 THOR MEDICAL ASA NK 0,20 EQUITY wird ex Kapitalmassnahme gehandelt am 16.12.2024 The instrument 8NN NO0010597883 THOR MEDICAL ASA NK 0,20 EQUITY is traded ex capital adjustment on 16.12.2024...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram